Comparative Pharmacology
Head-to-head clinical analysis: NIRAVAM versus TRIAZOLAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NIRAVAM versus TRIAZOLAM.
NIRAVAM vs TRIAZOLAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
NIRAVAM (alprazolam) is a benzodiazepine that potentiates GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and decreased excitability.
Triazolam is a benzodiazepine that binds to GABA-A receptors at the alpha-1 subunit, potentiating the inhibitory effects of GABA and increasing chloride ion influx, leading to neuronal hyperpolarization and sedation.
0.25–0.5 mg sublingually every 6–8 hours as needed; maximum 2 mg/day.
0.125-0.25 mg orally once daily at bedtime; maximum 0.5 mg/day.
None Documented
None Documented
Terminal elimination half-life: 8–14 hours (mean 10.5 h). Clinically, steady-state reached in ~3 days; accumulation minimal at typical dosing.
Clinical Note
moderateTriazolam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Triazolam is combined with Fluticasone propionate."
Clinical Note
moderateTriazolam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Triazolam."
Clinical Note
moderateTriazolam + Erythromycin
"The serum concentration of Erythromycin can be increased when it is combined with Triazolam."
Clinical Note
moderateTriazolam + Cyclosporine
1.5-5.5 hours (mean 2-4 hours) in healthy adults; prolonged in hepatic cirrhosis and elderly.
Renal: ~90% as metabolites (glucuronide conjugates and oxidized products), <5% unchanged. Fecal: <10%.
Primarily renal: approximately 80% as metabolites, less than 2% unchanged; biliary/fecal: minor (about 8-10%).
Category C
Category D/X
Benzodiazepine
Benzodiazepine
"The metabolism of Cyclosporine can be decreased when combined with Triazolam."